October 2004

Jane S. Ricciuti, RPh, MS

October 12, 2004

Introduction

The US Food and Drug Administration (FDA) approved Cymbalta (duloxetine hydrochloride) capsules for the management of the pain associated with diabetic peripheral neuropathy. This selective serotonin and norepinephrine reuptake inhibitor is the first drug specifically approved for this indication.

This month's column reviews FDA new product approvals and labeling changes for:

Antidepressants

Cymbalta (duloxetine) Capsules

Antihistamines

Clarinex (desloratadine) Syrup

Growth Hormones

Saizen (somatropin [rDNA origin]) for Subcutaneous Injection

Opioid Analgesics

Palladone (hydromorphone hydrochloride extended-release) Capsules

1 2 3 4 5

Next Section

Cite this: October 2004 - Medscape - Oct 12, 2004.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....

October 2004

Introduction

Tables

Authors and Disclosures

Authors and Disclosures

Comments

Email This

Feedback